DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

BLA 125320/S-177

SUPPLEMENT APPROVAL

Amgen, Inc.
Attention: Brian Stouch
Manager, Regulatory Affairs
One Amgen Center Drive
Mail Stop 17-1-A
Thousand Oaks, CA 91320-1799

Dear Mr. Stouch:

Please refer to your Supplemental Biologics License Application (sBLA), dated August 26, 2015, received August 26, 2015, and your amendments, submitted under section 351(a) of the Public Health Service Act for Xgeva® (denosumab, AMG 162; Human Monoclonal Antibody to RANK Ligand).

This "Prior Approval" supplemental biologics application provides for the addition of a new section to WARNINGS AND PRECAUTIONS subsection 5.6 (Hypercalcemia Following Treatment Discontinuation in Patients with Growing Skeletons), updates to ADVERSE REACTIONS subsection 6.1 (Clinical Trials Experience) to further strengthen the XGEVA USPI with regard to ONJ long-term risk, and removal of the Pregnancy Surveillance Program information from section 8.1 (Pregnancy).

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Elleni Alebachew, Regulatory Project Manager, at (301) 796-5225.

Sincerely,

{See appended electronic signature page}

Geoffrey Kim, M.D.
Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

GEOFFREY S KIM
03/02/2016